PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research0 citations

Real-World Uptake of gBRCA Testing as a Companion Diagnostic for Olaparib in Breast Cancer

Abstract PS2-06-30: Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with HER2-negative recurrent high-risk early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTomoe TajiMUMikiko UemuraYKYuri Kimura

Discussion

Loading...

Member takes

Overview

A multicenter study assesses gBRCA testing uptake in HER2-negative early breast cancer, highlighting significant gaps in awareness and access.

Key Points

  • To evaluate the real-world uptake of gBRCA testing among patients with HER2-negative recurrent high-risk early breast cancer in Japan.
  • Cross-sectional multicenter study conducted in Japan from January to December 2023.
  • Enrolled newly diagnosed patients with invasive HER2-negative breast cancer undergoing curative surgery.
  • Collected patient-level and institutional data regarding gBRCA testing and treatment outcomes.
  • 63.2% of enrolled patients underwent gBRCA testing.
  • 66% of untested patients were not informed about the testing option, primarily due to physician oversight.
  • 9.6% of tested patients had pathogenic variants, with 32 receiving olaparib treatment.

Cite This Study

Taji et al. (2026) studied this question.

synapsesocial.com/papers/6996a8a9ecb39a600b3ef8adhttps://doi.org/10.1158/1557-3265.sabcs25-ps2-06-30
View Full Paper
Ask AI
Bookmark
Share